Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Condition: Newly diagnosed diffuse large B-cell lymphoma (DLBCL)

Sponsor: MorphoSys AG

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND] This is a parallel arm, double-blind, placebo-controlled, multicenter, randomized, phase 3 study to investigate the efficacy and safety of tafasitamab plus lenalidomide as add-on therapy to R-CHOP (experimental arm) compared with R-CHOP (control arm) in adult patients with highintermediate and high-risk patients (defined as IPI 3-5 for patients > 60 years of age and aaIPI2-3 for patients ≤ 60 years of age) with newly-diagnosed, previously untreated DLBCL.


Go To Trial Homepage